- Home
- CANF vs LFWD Comparison
CANF vs LFWD Comparison
Compare CANF & LFWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- LFWD
- Stock Information
- Founded
- CANF 1994
- LFWD 2001
- Country
- CANF Israel
- LFWD Israel
- Employees
- CANF N/A
- LFWD N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- LFWD
- Sector
- CANF Health Care
- LFWD
- Exchange
- CANF Nasdaq
- LFWD NYSE
- Market Cap
- CANF 14.8M
- LFWD 15.8M
- IPO Year
- CANF N/A
- LFWD 2014
- Fundamental
- Price
- CANF $1.10
- LFWD $1.21
- Analyst Decision
- CANF Strong Buy
- LFWD Strong Buy
- Analyst Count
- CANF 2
- LFWD 3
- Target Price
- CANF $14.00
- LFWD $9.00
- AVG Volume (30 Days)
- CANF 68.3K
- LFWD 152.9K
- Earning Date
- CANF 06-17-2025
- LFWD 05-15-2025
- Dividend Yield
- CANF N/A
- LFWD N/A
- EPS Growth
- CANF N/A
- LFWD N/A
- EPS
- CANF N/A
- LFWD N/A
- Revenue
- CANF $674,000.00
- LFWD $25,414,000.00
- Revenue This Year
- CANF $461.72
- LFWD $12.04
- Revenue Next Year
- CANF N/A
- LFWD $40.58
- P/E Ratio
- CANF N/A
- LFWD N/A
- Revenue Growth
- CANF N/A
- LFWD 41.92
- 52 Week Low
- CANF $0.98
- LFWD $1.18
- 52 Week High
- CANF $4.69
- LFWD $4.77
- Technical
- Relative Strength Index (RSI)
- CANF 46.91
- LFWD 39.21
- Support Level
- CANF $1.07
- LFWD $1.21
- Resistance Level
- CANF $1.12
- LFWD $1.27
- Average True Range (ATR)
- CANF 0.03
- LFWD 0.06
- MACD
- CANF 0.02
- LFWD 0.00
- Stochastic Oscillator
- CANF 75.00
- LFWD 21.43
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About LFWD REWALK ROBOTICS LTD
Lifeward Ltd is a medical device company that designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering functional and health benefits in clinical settings as well as in the home and community. Its product offerings are the ReWalk Exoskeleton, the ReStore Exo-Suit, the MyoCycle FES bikes, and AlterG Anti-Gravity systems. It operates through markets in the United States, Israel, and Germany.